Here's Why The Medicines Company Jumped 60% in November
Terrific clinical trial data followed by a $9.7 billion buyout offer gave investors lots to be thankful for.
The Medicines Company(MDCO)
NASDAQ
MDCO
A pharmaceutical company provides innovative, cost effective acute care hospital products to the worldwide hospital marketplace.
Interactive Chart
News & Analysis: The Medicines Company
The Fool has written over 100 articles on The Medicines Company.
A 45% Premium: Here's Why The Medicines Company Is Worth More to Novartis Than It Was to You
Understanding why can help you identify the next takeout target.
Stock Market News: Novartis Makes a Deal; Saudi Aramco IPO Picks Up Steam
The stock market got off to a solid start in the holiday-shortened week.
Why The Medicines Company Stock Is Soaring Today
Novartis added another key piece to the puzzle over the weekend.
Here’s Why The Medicines Company Jumped Higher Again Today
A buyout rumor has investors hopeful.
Here's Why The Medicines Company Moved Higher Today
Clinical data for cholesterol-lowering drug inclisiran looks good.
Medicines Co (MDCO) Q3 2019 Earnings Call Transcript
MDCO earnings call for the period ending September 30, 2019.
The Medicines Company Surges on Positive Drug Trial Results
The company's flagship cholesterol treatment shows major potential.
The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success
Investors should go to the source.
Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
